Project Grant R34HL173301
Award Date
4/21/25
Completion Date
3/31/27
Dollars Obligated
$392K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the impact of restrictive drug coverage policies on prescribing, adherence, and clinical outcomes for heart failure patients. The awardee, New York University School of Medicine, will utilize a large integrated database to quantify the effects of these policies, develop models to identify vulnerable patient...
This federal Project Grant award of $2,428,701 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comprehensive, prospective evaluation of 1,000 pregnant individuals with cardiovascular disease (CVD) across 33 partner sites. The study aims to: Identify patient characteristics associated with adverse pregnancy outcomes, maternal adverse cardiac events, neonatal adverse clinical events, and quality of life, with a focus on racial...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $785,951 to New York University (NYU) School of Medicine to conduct research on improving provider adoption of clinical decision support tools for pulmonary embolism risk assessment. The project aims to evaluate the impact of incorporating behavioral economic "nudge" strategies into a clinical decision support tool for managing pulmonary embolism...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $593,250 to New York University School of Medicine to conduct a Phase II pragmatic randomized trial of an mHealth-enabled cardiac rehabilitation intervention for patients with ischemia and no obstructive coronary artery disease (INOCA). The 4-year study aims to evaluate whether the mHealth-enabled cardiac rehabilitation program...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $695,882 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to New York University School of Medicine. The funding supports research on therapeutic modulation of atrial remodeling to prevent and reverse atrial fibrillation (AF), a leading cause of stroke and cardiovascular morbidity. The research investigates the use of all-trans retinoic acid (ATRA), a vitamin A derivative, to normalize metabolic...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), awarded a $299,604 Project Grant to Case Western Reserve University (CWRU) to develop and validate a novel transfer volume regression approach for predicting major cardiovascular events, including stroke, heart attack, heart failure, and death. The project, running from September 1, 2024 to August 31, 2028, aims to create a standardized, fairness-aware, and user-friendly...
This $100,050 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to conduct comparative effectiveness research on the role of cardiometabolic agents, including glucagon-like peptide 1 receptor agonists (GLP1-RA), sodium-glucose cotransporter-2 inhibitors (SGLT2I), and metformin, as well as bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research will leverage the Veteran...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $874,792 to Vanderbilt University Medical Center from July 2024 to June 2028. The project aims to address residual atherosclerotic cardiovascular disease (ASCVD) risk among patients who continue to experience myocardial infarctions or strokes despite treatment to lower LDL-cholesterol and blood pressure. The key objectives are to: (1)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop integrated precision medicine models to improve the identification of cardiovascular disease (CVD) patients treated with statins or antiplatelet therapy who are at increased risk for adverse drug responses and adverse outcomes. The award, worth $114,375, will utilize data from the All of Us Research Program to evaluate...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 5-year, $394,200 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Weill Medical College of Cornell University to develop and pilot test an innovative behavioral intervention called COPDHEART. The goal of COPDHEART is to improve cardiovascular health among Black adults with chronic obstructive pulmonary disease (COPD) by increasing the uptake of evidence-based cardiovascular health recommendations....